consideration of possible contraindications and side effect profile in patients without evidence of severe PsA or severe psoriasis and in those at risk for liver toxicity (Table 1 3 Active PsA despite treatment with an OSM (Table 2 4 In patients with active PsA despite OSM therapy, switching to a TNFi, an IL-17i, or an IL-12/23i biologic is recommended over switching to a different OSM (Table 2 4 ent OSM may be used rather than a TNFi in the presence of contraindications to TNFi biologics. A